We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Finnish Study Describes Activators of SIRT6 Gene

By LabMedica International staff writers
Posted on 17 Apr 2018
A team of Finnish researchers conducted a study to evaluate the differences in chemical features between inhibitors and activators of the cancer-related SIRT6 gene.

SIRT6 (Sirtuin 6) is a chromatin-associated enzyme that is required for normal base excision repair of DNA damage in mammalian cells. More...
Deficiency of SIRT6 in mice leads to abnormalities that overlap with aging-associated degenerative processes. SIRT6 also promotes the repair of DNA double-strand breaks by the process of non-homologous end joining.

Flavonoids are polyphenolic secondary metabolites synthesized by plants and fungi with various pharmacological effects. Due to their many classes of biological activity, they have been studied extensively in drug development. Flavonoids have been shown to modulate the activity of a NAD+-dependent histone deacetylase, SIRT6. Since SIRT6 has been implicated in longevity, metabolism, DNA-repair, and inflammatory response reduction, it is an interesting target in inflammatory and metabolic diseases as well as in cancer.

Investigators at the University of Eastern Finland (Kuopio, Finland) reported in the March 7, 2018, online edition of the journal Scientific Reports that flavonoids could alter SIRT6 activity in a structure dependent manner. Catechin derivatives with galloyl moiety displayed significant inhibition potency against SIRT6 at 10 microMolar concentration. The most potent SIRT6 activator, cyanidin, belonged to the family of anthocyanidins, and produced a 55-fold increase in SIRT6 activity compared to the three to 10-fold increase for the others. Cyanidin was also found to significantly increase SIRT6 expression in human colon adenocarcinoma Caco-2 cells. Cyanidin also decreased the expression of the TWIST1 and GLUT1 cancer promoter genes in Caco-2 cells, while increasing the expression of the tumor suppressor FOXO3 gene in the cells.

Results from docking studies indicated possible binding sites for SIRT6 inhibitors and activators. Inhibitors likely attached in a manner that could disturb NAD+ binding. The putative activator-binding site was found next to a loop near the acetylated peptide substrate-binding site. In some cases, the activators changed the conformation of this loop suggesting that it might play a role in SIRT6 activation.

"The most interesting results of our study relate to cyanidin, which is an anthocyanin found abundantly in wild bilberry, blackcurrant, and lingonberry," said first author Dr. Minna Rahnasto-Rilla, pharmacology researcher at the University of Eastern Finland.

Related Links:
University of Eastern Finland


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.